Immunogenicity of HLA-A1-restricted peptides derived from S100A4 (metastasin 1) in melanoma patients
- First Online:
- Cite this article as:
- Hofmeister-Mueller, V., Vetter-Kauczok, C.S., Ullrich, R. et al. Cancer Immunol Immunother (2009) 58: 1265. doi:10.1007/s00262-008-0640-0
- 385 Downloads
S100A4 (metastasin 1) belongs to the S100 family of Ca2+ binding proteins. While not present in most differentiated adult tissues, S100A4 is upregulated in the micromilieu of tumors. It is primarily expressed by tumor-associated macrophages, fibroblasts, and tumor endothelial cells. Due to its strong induction in tumors S100A4 is a promising target for cancer immunotherapy. By reverse immunology, using epitope prediction programs, we identified 3 HLA-A1-restricted peptide epitopes (S100A4 A1-1, A1-2, and A1-3) which are subject to human T cell responses as detected in peripheral blood of melanoma patients by means of IFN-γ ELISPOT and cytotoxicity assays. In addition, IFN-γ responses to S100A4 A1-2 can not only be induced by stimulation of T cells with peptide-loaded DC but also by stimulation with S100A4 protein-loaded DC, indicating that this epitope is indeed generated by processing of the endogenously expressed protein. In addition, S100A4 A1-2 reactive T cells demonstrate lysis of HLA-A1+ fibroblasts in comparison to HLA-A1− fibroblasts. In summary, this HLA-A1-restricted peptide epitope is a candidate for immunotherapeutical approaches targeting S100A4-expressing cells in the tumor stroma.
KeywordsCTLHLA-A1 epitopeMelanomaMetastasin 1S100A4Tumor stroma
S100A4, also referred to as metastasin 1 (mts1), fibroblast-specific protein 1 (FSP1), placental calcium-binding protein, CAPL, calvasculin, p9Ka, pEL-98, 18A2, or 42A belongs to the family of EF-hand calcium-binding proteins. S100A4 has both intracellular and extracellular functions. By binding to different target molecules S100A4 influences cell motility, invasion, adhesion, proliferation, apoptosis, remodeling of the extracellular matrix, and angiogenesis [15, 41]. S100A4 expression is enhanced under several pathological conditions including cancer, where it might be expressed in and released from tumor cells, tumor stroma cells or both [8, 48, 49]. Indeed, S100A4 expression was demonstrated in many cell types participating in formation of the tumor stroma, e.g., cancer-associated fibroblasts, tumor endothelial cells, and tumor-associated macrophages. Notably, an extensive study in breast cancer describes preferential expression of S100A4 in macrophages and fibroblasts . All these stroma cells contribute to the development and progression of cancer by secretion of growth and angiogenic factors or extracellular matrix degrading enzymes leading to enhanced tumor cell proliferation, invasion, angiogenesis, and finally metastasis and in consequence are potential anti-cancer therapeutical targets [20, 21, 31]. S100A4 itself has been implicated in disease development and progression, as it promotes the oncogenic phenotype of tumor cells. Its expression has been described for a variety of cancer entities, e.g., carcinoma of the breast [12, 22, 30, 37, 46, 54], ovary , thyroid [23, 36, 57], esophagus , bladder [1, 11], gallbladder , colon , colorectum [10, 19], pancreas [2, 40, 45] and prostate , gastric cancers [14, 26, 55], lung [27, 34], and brain cancers [44, 52]. S100A4 expression has also been described in primary and metastatic melanoma [3, 32, 39]. Elevated S100A4 levels are associated with a more aggressive phenotype and a poor prognosis [11, 18, 26, 36]. Due to its involvement in disease development and progression and its broad expression in the tumor microenvironment, S100A appears as an attractive target for cancer therapy that should allow the destruction of the tumor directly by targeting the cancer cells themselves and indirectly by destroying the supporting tumor stroma cells. Indeed, the destruction of the tumor stroma may be essential to eradicate tumors .
Up to date, approaches for down-regulation of S100A4 expression by ribozymes  or RNA interference [51, 52] have demonstrated the feasibility of S100A4-directed anti-tumor therapies. For example, the reduction of its expression in a murine model of thyroid carcinoma was accompanied by enhanced sensitivity to chemotherapy . To analyse if S100A4 may be a therapeutic target for cancer immunotherapy, we applied reverse immunology to identify S100A4-derived T cell epitopes and demonstrated their immunogenicity ex vivo as well as the occurrence of spontaneous immune responses against these in melanoma patients.
Materials and methods
Cells and cell lines
The HLA-A1+ lymphoblastoid cell line BM36.1 and the melanoma cell lines MelJuso, Mel2a, and Mel888 were cultured in RPMI 1640/10% FCS supplemented with 100 U penicillin/ml and 100 μg streptomycin/ml.
Human skin fibroblasts were isolated by incubation of normal skin tissue pieces obtained from the margins after resection of nevi or cancerous lesions in 0.25% collagenase (Collagenase D, Boehringer Mannheim, Mannheim, Germany) and 0.1 mg/ml DNAse. The resulting suspension was filtered through a fine mesh. Obtained cells were maintained in RPMI 1640 supplemented with 10% FCS.
After informed consent PBL were collected from HLA-A1+ patients (n = 16) with advanced malignant melanoma. PBL were isolated using Lymphoprep separation (Axis-Shield PoC AS, Oslo, Norway) according to the manufacturer’s instructions and used directly or after cryopreservation. PBL were cultured in RPMI 1640/10% human AB serum. CD8+ T cells were negatively selected using the CD8+ T Cell Isolation Kit II (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer’s recommendations.
Dendritic cells were generated from PBL by adherence on culture dishes at 37°C for 60 min in RPMI 1640 enriched with 10% human AB serum. Adherent monocytes were cultured in RPMI 1640 supplemented with 10% human AB serum in the presence of IL-4 (1,000 U/ml) and GM-CSF (800 U/ml) for 6 days. DCs were matured by addition of IL1β (2 ng/ml), IL-6 (1,000 U/ml), TNFα (10 ng/ml), and PGE2 (1 μg/ml). The next day the resulting mature DC were pulsed with 10 μM peptide and 3 μg β2-microglobulin/ml overnight at 37°C. For loading of DC with S100A4 protein 1 × 106 immature DC/ml were incubated with 50 μg protein/ml overnight before adding the maturing cocktail.
After pre-treatment with 0.1% pronase (Roche Diagnostics GmbH, Mannheim, Germany) for 20 min at 37°C and proteinase K (Dako, Hamburg, Germany) for 10 min at room temperature, respectively, paraffin sections of normal skin, nevi, and melanoma were stained with S100A4-specific rabbit antiserum or anti CD68 clone PG-M1 (Dako) and the appropriate DakoCytomation Envison+ Systems (Dako) followed by the Vector Nova red system (Vector Laboratories, Burlingame, USA) according to the manufacturer’s instructions. As negative control sections were stained with normal rabbit antiserum or without primary antibody, respectively.
S100A4 nonamer peptides
HLA-A1-restricted nonamer peptides derived from the full-length human S100A4 protein were selected using both SYFPEITHI  and BIMAS  peptide binding algorithms freely available via the internet (http://www.syfpeithi.de/ and http://bimas.cit.nih.gov/molbio/hla_bind/). The peptides were synthesized by GenScript Corporation (Piscataway, New Jersey, USA). HLA-A1-restricted peptides derived from influenza nucleoprotein (NP) peptide 44–52 (CTELKLSDY)  were used as controls.
The human IFN-γ ELISPOT assay was used to quantify peptide epitope-specific IFN-γ-releasing effector cells as described previously . Briefly, nitrocellulose-bottomed 96-well plates (MultiScreen MAIP N45, Millipore GmbH, Schwalbach, Germany) were activated with 35% ethanol, washed with PBS, and coated with anti-IFN-γ Ab (1-D1K, Mabtech, Hamburg, Germany). The wells were washed and blocked by X-vivo medium (Cambrex Biosciences, Verviers, Belgium) before adding 1 × 104 stimulator BM36.1 cells loaded with or without 10 μM peptide and 3 × 105, 1 × 105, or 3 × 104 effector cells. To minimize background in samples stimulated with DC preincubated with S100A4 protein or peptides, only 1 × 105, 3 × 104, and 1 × 104 effector cells were used. After incubation overnight the wells were washed with PBS followed by addition of biotinylated secondary Ab (7-B6-1-Biotin, Mabtech, diluted in PBS/1% BSA). The plates were incubated for 2 h, washed, and streptavidin-enzyme conjugate (Streptavidin-ALP-PQ, Mabtech, diluted in PBS/1% BSA) was added. Incubation at room temperature for 1 h was followed by washing with wash buffer and substrate buffer (0.1 M NaCl, 50 mM MgCl2, 0.1 M Tris–HCl, pH 9.5), and addition of enzyme substrate NBT/BCIP (Mabtech). The reaction was stopped by washing with tap water upon the appearance of dark purple spots. Spots were counted using the ImmunoSpot Series 2.0 Analyzer (CTL Cellular Technology Ltd., Schwäbisch Gmünd, Germany). The peptide-specific CTL frequency was calculated from the numbers of spot-forming cells. All assays were performed at least in duplicates. To extend the sensitivity of the ELISPOT assay, PBL were stimulated once in vitro before analysis. At day 0, PBL were plated in a cell concentration of 1 × 106/ml in 6-well plates (Greiner GmbH, Frickenhausen, Germany) in X-vivo medium (Cambrex) supplemented with 10% heat inactivated human AB serum in the presence of 10 μM peptide (GeneScript Corporation). Alternatively, 1 × 105 irradiated (50 Gy) DC/ml loaded with S100A4 protein or peptide were used for stimulation of 1 × 106 PBL/ml in the presence of 40 U IL-2/ml (Proleukin, Chiron GmbH, Munich, Germany). IL-2 was added every 3–4 days to the culture. The cultured cells were tested for reactivity in ELISPOT on day 7.
For the microcytotoxicity assay, 2 × 102 target cells/well were plated in Terasaki plates (Nunc, Wiesbaden, Germany) for 24 h. After 24 h, the in vitro prestimulated lymphocytes were added at effector:target ratios of 30:1 and 10:1 in a final volume of 10 μl . After overnight incubation, the plates were washed, fixed with −20°C cold methanol, and stained with Giemsa-Solution (Merck, Darmstadt, Germany). All stained target cells were counted and the percent of lysis was calculated. As negative control target cells only, without adding effector cells, were used. In addition, specific lysis of fibroblasts or Mel2a was analysed in a 4 hour standard chromium release assay. Mel2a targets were preincubated with or without 10 μM peptide, 20 μg/ml W6/32 antibody (Dako, Hamburg, Germany), or IgG2a isotype control antibody (Dianova, Hamburg, Germany). Cold targets were preincubated with 10 μM S100A4 A1-2 or irrelevant peptide derived from influenza NP 44–52.
Sequence similarity search
A search for proteins containing the identified S100A4 peptides was done using the protein blast tool available at http://www.ncbi.nlm.nih.gov.
Statistical analysis was performed using GraphPad Prism version 4.03 for Windows (GraphPad Software, San Diego California USA, www.graphpad.com).
S100A4 is upregulated in the tumor micromilieu
Spontaneous IFN-γ responses to HLA-A1-restricted S100A4-derived peptide epitopes
Position, amino acid sequence, and peptide binding prediction of HLA-A1-restricted S100A4 peptides
Peptide- versus protein-induced T cell responses
To further evaluate the immunogenicity of both S100A4 and the S100A4-derived peptides, we stimulated lymphocytes from HLA-A1+ donors in vitro with DC which where either given the possibility to process the whole protein or pulsed with the peptides. The response was measured by IFN-γ release ELISPOT assay to either protein or peptides. This analysis revealed that, in contrast to the epitopes S100A4 A1-1 and A1-3, IFN-γ responses to the peptide S100A4 A1-2 were not only induced by the respective peptides but also after in vitro stimulation using DC which processed the whole protein (Fig. 2d). The lack of IFN-γ response to the S100A4 A1-1 and A1-3 peptides after stimulation with S100A4 protein-loaded DC indicates that in this case no unspecific or CD4+ T cell responses were induced. This indicates that only the S100A4 A1-2 epitope is cross-presented and indeed generated by natural processing of the antigen, whereas the epitopes A1-1 and A1-3 albeit binding to HLA-A1 are not. Furthermore, after prestimulation with DC which processed S100A4 protein the IFN-γ release response to the complete S100A4 protein was significantly higher than in the response to the S100A4 A1-2 peptide indicating that other epitopes than the S100A4 A1-2 contribute to the anti S100A4 immune reaction (Fig. 2e). Although the majority of the additional immune response can likely be attributed to CD4+ T cells, it is also feasible that other MHC class I epitopes are cross-presented.
Cytotoxic activity of S100A4-specific T cells
Comparison of S100A4-derived peptides with S100 family members
Melanoma is an immunogenic tumor, known to induce spontaneous immune responses which may result in partial regressions of primary tumors. This observation has led to the development of several immune therapeutic approaches including tumor specific vaccination. We have selected S100A4 as immunological target molecule and verified its upregulation in the tumor micromilieu of melanoma (Fig. 1). In addition, a correlation between S100A4 protein expression in melanoma and aggressive phenotype, especially in early superficial spreading melanomas, has been described . Notably, in the presented report we characterized a HLA-A1-restricted peptide epitope, S100A4 A1-2, that is generated by processing of the complete S100A4 protein, demonstrated by reactivity to S100A4 protein-loaded DC, HLA-A1+ fibroblasts, and HLA-A1+ melanoma cells (Figs. 2 and 3). Interestingly, two other HLA-A1-restricted peptide epitopes were predicted by the used computer algorithms and ex vivo immune responses to these epitopes were detected in peripheral blood of melanoma patients, as well; however, when lymphocytes were stimulated with DC which processed the whole recombinant S100A4 protein only responses to one peptide, S100A4 A1-2, were induced. Vice versa only S100A4 A1-2 reactive T cells released IFN-γ in response to S100A4 processing DC or killed target cells without these being pulsed with peptide. This observation illustrates the limitations of reverse immunology and confirms the need for confirmation assays demonstrating the presentation of identified epitopes by the desired target cells, e.g., S100A4 A1-2 on fibroblasts or melanoma cells.
The presented results suggest that T cell responses to S100A4 A1-2 can be induced by vaccination, e.g., allowing the development of an immune therapy with a low risk of inducing immune escape variants since S100A4 is expressed both in melanoma cells as well as in the genetically relatively stable tumor stroma cells, which promote tumor progression. However, it has to be noted that S100A4 expression is not completely restricted to tumor cells and tumor stroma cells. Although S100A4 expression has not been detected in most normal tissues, e.g., obtained from the breast, colon, thyroid, kidney, and pancreas, its expression has been described for lymphoid organs and white matter astrocytes [16, 28]. Moreover, S100A4 is upregulated in injured tissues [4, 6, 29, 50]. Another concern regarding side effects is cross targeting of other S100 family members. The S100 proteins are widely expressed and fulfill diverse functions . The amino acid identity of S100A4 and other S100 proteins is up to 61% (S100A2). However, Blast search for the S100A4 A1-2 peptide resulted in one other identical hit apart from S100A4 only, i.e., leukemia multidrug resistance associated protein (Fig. 4). Leukemia multidrug resistance associated protein has once been described so far, in the leukemia cell line HL60 . Although predictable side effects using S100A4 A1-2 due to cross reaction with other S100A4 family members are low, possible adverse side effects of S100A4 targeting therapies have to be addressed in future studies.
In summary, S100A4 is an attractive target for anti-cancer therapy as its expression is elevated in the tumor micromilieu, both in tumor and tumor stroma cells. Hence, it is possible to develop strategies to simultaneously target different cell types contributing to tumor progression. The identification of an HLA-A1-restricted peptide derived from S100A4 will allow to investigate if active immunisation to S100A4+ cells is an feasible option for anti-cancer immunotherapy.
This work was funded by the Deutsche Forschungsgemeinschaft/DFG (KFO 124).
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.